Program
betamethasone dipropionate
Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.
Its studies are mostly in Psoriasis · Skin and Connective Tissue Diseases · Dermatitis, Atopic, led by 5 companies.
Drug pageBetamethasone dipropionate: every studyMany companies study it; this page follows only the 26 they lead. All 42 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LEO Pharma | 180 open or running | phase 4since Nov 3, 2005 | Sep 15, 2005 | none ahead |
| MC2 Therapeuticsits history only | 50 open or running | phase 3since Oct 9, 2017 | Oct 9, 2017 | none ahead |
| Glenmark Pharmaceuticals Ltd. Indiaits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
| Huadong Medicineits history only | 10 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | none ahead |
| Primus Pharmaceuticalsits history only | 10 open or running | phase 4since Apr 13, 2016 | Apr 13, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of LEO Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Sep 15, 2005.
- Oct 21, 2005Phase 3 study in Psoriasis of ScalpNCT00243464 · 300 enrolled · Belgium, Canada, Denmark and more
- Nov 3, 2005Phase 4 study in Psoriasis VulgarisNCT00248456 · 320 enrolled · China
- Dec 8, 2005Phase 2 study in Psoriasis VulgarisNCT00263718 · 360 enrolled · Canada, Germany, Ireland and more
- Jan 5, 2009Phase 2 study in Psoriasis VulgarisNCT00817219 · 33 enrolled · United States
- Apr 2, 2009Phase 2 study in Psoriasis VulgarisNCT00875277 · 24 enrolled · France
- Feb 16, 20122 phase 2 studies in Psoriasis VulgarisNCT01536938, NCT01536886
- May 8, 2012Phase 2 study in Psoriasis VulgarisNCT01600222 · 37 enrolled · Canada
- May 28, 2013Phase 3 study in Psoriasis VulgarisNCT01866163 · 426 enrolled · United States
- Aug 27, 2013Phase 1 study in Psoriasis VulgarisNCT01935869 · 224 enrolled · France
- Jan 27, 2015Phase 1 study in Skin and Connective Tissue DiseasesNCT02355639 · 16 enrolled · Germany
- Feb 25, 2015Phase 1 study in Dermatitis, AtopicNCT02376049 · 30 enrolled · Canada, Israel
- Mar 12, 2015Phase 2 study in Psoriasis VulgarisNCT02387853 · 117 enrolled · United States, Netherlands, Poland and more
- Nov 22, 2016Phase 1 study in Psoriasis VulgarisNCT02973776 · 36 enrolled · France
- Jun 16, 2023Phase 3 study in Stable Plaque PsoriasisNCT05919082 · 604 enrolled · China
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 18 LEO Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05919082Stable Plaque Psoriasis · China | 3 | Completed | Feb 23, 2024 | 604 |
| NCT02973776Psoriasis Vulgaris · France | 1 | Completed | Feb 2017 | 36 |
| NCT02387853Psoriasis Vulgaris · United States, Netherlands, Poland and more | 2 | Completed | Mar 28, 2018 | 117 |
| NCT02376049Dermatitis, Atopic · Canada, Israel | 1 | Completed | Jul 2015 | 30 |
| NCT02355639Skin and Connective Tissue Diseases · Germany | 1 | Completed | Apr 2015 | 16 |
| NCT01935869Psoriasis Vulgaris · France | 1 | Completed | Nov 2013 | 224 |
| NCT01866163Psoriasis Vulgaris · United States | 3 | Completed | Oct 2013 | 426 |
| NCT01600222Psoriasis Vulgaris · Canada | 2 | Completed | May 2013 | 37 |
| NCT01536938Psoriasis Vulgaris · United States | 2 | Completed | Sep 2012 | 303 |
| NCT01536886Psoriasis Vulgaris · United States | 2 | Completed | Sep 2012 | 376 |
| NCT00875277Psoriasis Vulgaris · France | 2 | Completed | May 2009 | 24 |
| NCT00817219Psoriasis Vulgaris · United States | 2 | Completed | Dec 2011 | 33 |
| NCT00263718Psoriasis Vulgaris · Canada, Germany, Ireland and more | 2 | Completed | 360 | |
| NCT00248456Psoriasis Vulgaris · China | 4 | Completed | 320 | |
| NCT00243464Psoriasis of Scalp · Belgium, Canada, Denmark and more | 3 | Completed | 300 | |
| NCT00216879Psoriasis of Scalp · Canada, Denmark, France and more | 3 | Completed | 800 | |
| NCT00216840Psoriasis of Scalp · Belgium, Canada, Finland and more | 3 | Completed | 1,350 | |
| NCT00216827Psoriasis of Scalp · Canada, Denmark, France and more | 3 | Completed | 1,485 |
How it is read
Names in the registry
- “LEO 90100”, 7 entries
- “MC2-01 cream”, 4 entries
- “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
- “MC2-01 Cream”, 2 entries
- “Calcipotriene plus betamethasone dipropionate ointment”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 24 studies
- Skin and Connective Tissue Diseases, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.